JP2016501223A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016501223A5 JP2016501223A5 JP2015545193A JP2015545193A JP2016501223A5 JP 2016501223 A5 JP2016501223 A5 JP 2016501223A5 JP 2015545193 A JP2015545193 A JP 2015545193A JP 2015545193 A JP2015545193 A JP 2015545193A JP 2016501223 A5 JP2016501223 A5 JP 2016501223A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- alkyl
- heteroaryl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 61
- 125000003118 aryl group Chemical group 0.000 claims 35
- 125000001072 heteroaryl group Chemical group 0.000 claims 31
- 229910052799 carbon Inorganic materials 0.000 claims 20
- 150000001204 N-oxides Chemical class 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 18
- 229910052739 hydrogen Inorganic materials 0.000 claims 15
- 229920006395 saturated elastomer Polymers 0.000 claims 15
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 14
- 229910052717 sulfur Inorganic materials 0.000 claims 14
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 13
- 125000000753 cycloalkyl group Chemical group 0.000 claims 12
- 229910052760 oxygen Inorganic materials 0.000 claims 12
- 229910052757 nitrogen Inorganic materials 0.000 claims 7
- 125000004429 atom Chemical group 0.000 claims 6
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 6
- 125000006747 (C2-C10) heterocycloalkyl group Chemical group 0.000 claims 5
- -1 fused ring Chemical group 0.000 claims 5
- 125000004404 heteroalkyl group Chemical group 0.000 claims 5
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims 3
- 125000003003 spiro group Chemical group 0.000 claims 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 2
- 125000006584 (C3-C10) heterocycloalkyl group Chemical group 0.000 claims 2
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims 2
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 claims 1
- 229940088872 Apoptosis inhibitor Drugs 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000000158 apoptosis inhibitor Substances 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 150000001721 carbon Chemical class 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 108091006086 inhibitor proteins Proteins 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261731794P | 2012-11-30 | 2012-11-30 | |
| US61/731,794 | 2012-11-30 | ||
| PCT/US2013/072064 WO2014085489A1 (en) | 2012-11-30 | 2013-11-26 | Inhibitor of apoptosis protein (iap) antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018101004A Division JP2018162256A (ja) | 2012-11-30 | 2018-05-25 | アポトーシス阻害タンパク質（ｉａｐ）のアンタゴニスト |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016501223A JP2016501223A (ja) | 2016-01-18 |
| JP2016501223A5 true JP2016501223A5 (enExample) | 2016-12-15 |
| JP6382831B2 JP6382831B2 (ja) | 2018-08-29 |
Family
ID=50828427
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015545193A Active JP6382831B2 (ja) | 2012-11-30 | 2013-11-26 | アポトーシス阻害タンパク質（ｉａｐ）のアンタゴニスト |
| JP2018101004A Pending JP2018162256A (ja) | 2012-11-30 | 2018-05-25 | アポトーシス阻害タンパク質（ｉａｐ）のアンタゴニスト |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018101004A Pending JP2018162256A (ja) | 2012-11-30 | 2018-05-25 | アポトーシス阻害タンパク質（ｉａｐ）のアンタゴニスト |
Country Status (5)
| Country | Link |
|---|---|
| US (5) | US9546174B2 (enExample) |
| EP (1) | EP2925764B1 (enExample) |
| JP (2) | JP6382831B2 (enExample) |
| CA (1) | CA2896577C (enExample) |
| WO (1) | WO2014085489A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6382831B2 (ja) | 2012-11-30 | 2018-08-29 | サンフォード−バーンハム メディカル リサーチ インスティテュート | アポトーシス阻害タンパク質（ｉａｐ）のアンタゴニスト |
| CA2974651A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
| US10300074B2 (en) | 2014-06-04 | 2019-05-28 | Sanford Burnham Prebys Medical Discovery Institute | Use of inhibitor of apoptosis protein (IAP) antagonists in HIV therapy |
| WO2016079527A1 (en) | 2014-11-19 | 2016-05-26 | Tetralogic Birinapant Uk Ltd | Combination therapy |
| WO2016097773A1 (en) | 2014-12-19 | 2016-06-23 | Children's Cancer Institute | Therapeutic iap antagonists for treating proliferative disorders |
| CN109152843A (zh) | 2016-05-20 | 2019-01-04 | 豪夫迈·罗氏有限公司 | Protac抗体缀合物及其使用方法 |
| US10870663B2 (en) | 2018-11-30 | 2020-12-22 | Glaxosmithkline Intellectual Property Development Limited | Compounds useful in HIV therapy |
| AU2019390729B2 (en) * | 2018-11-30 | 2022-08-11 | Glaxosmithkline Intellectual Property Development Limited | Compounds useful in HIV therapy |
| WO2020148447A1 (en) | 2019-01-17 | 2020-07-23 | Debiopharm International S.A. | Combination product for the treatment of cancer |
| CN110028508B (zh) * | 2019-05-16 | 2021-05-28 | 南京华威医药科技集团有限公司 | 一种抗肿瘤的重氮双环类细胞凋亡蛋白抑制剂 |
| CA3148504A1 (en) | 2019-08-08 | 2021-02-11 | Institute For Cancer Research D/B/A/ The Research Institute Of Fox Chase Cancer Center | Combination therapy for treatment of cancer |
| EP4034102A1 (en) | 2019-09-25 | 2022-08-03 | Debiopharm International SA | Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma |
| EP4058454A4 (en) * | 2019-11-08 | 2023-12-13 | Sanford Burnham Prebys Medical Discovery Institute | APOPTOSIS INHIBITORS (IAP) PROTEIN ANTAGONISTS |
| WO2021222614A1 (en) * | 2020-04-30 | 2021-11-04 | Sanford Burnham Prebys Medical Discovery Institute | Inhibitor of apoptosis (iap) protein antagonists |
| WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
| US20250129099A1 (en) * | 2021-11-04 | 2025-04-24 | Sanford Burnham Prebys Medical Discovery Institute | Inhibitor of apoptosis (iap) protein antagonists |
| AR131299A1 (es) * | 2022-12-09 | 2025-03-05 | Debiopharm Int Sa | Nuevos inhibidores de iap, métodos para fabricarlos y usos de los mismos |
| WO2025090605A1 (en) * | 2023-10-24 | 2025-05-01 | University Of Houston System | Combination of iap inhibitors and cellular kinase inhibitors, such as ponatinib, for use in the treatment of cancer or pulmonary diseases, such as copd, cystic fibrosis, pulmonary fibrosis and covid-19 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5455242A (en) | 1991-09-27 | 1995-10-03 | Merrell Dow Pharmaceuticals Inc. | Carboxyalkyl tricyclic derivatives useful as inhibitors of enkephalinase and ace |
| US5457196A (en) | 1991-09-27 | 1995-10-10 | Merrell Dow Pharmaceuticals Inc. | 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE |
| DE69329701T2 (de) | 1992-10-30 | 2001-05-10 | Merrell Pharmaceuticals Inc., Cincinnati | Mercaptoacetylamid substituiertes bizyclisches laktam zur verwendung als enkephalinase und ace-hemmer |
| US5508272A (en) | 1993-06-15 | 1996-04-16 | Bristol-Myers Squibb Company | Compounds containing a fused bicycle ring and processes therefor |
| FR2803594B1 (fr) * | 2000-01-11 | 2002-07-19 | Centre Nat Rech Scient | Oligomeres de mimes contraints non peptidiques de dipeptides ou de tripeptides, et leurs utilisations |
| US7932382B2 (en) * | 2004-01-16 | 2011-04-26 | The Regents Of The University Of Michigan | Conformationally constrained Smac mimetics and the uses thereof |
| MXPA06014969A (es) | 2004-07-02 | 2007-02-08 | Genentech Inc | Inhibidores de iap. |
| WO2006010118A2 (en) | 2004-07-09 | 2006-01-26 | The Regents Of The University Of Michigan | Conformationally constrained smac mimetics and the uses thereof |
| CA2573644A1 (en) | 2004-07-12 | 2006-02-16 | Idun Pharmaceuticals, Inc. | Tetrapeptide analogs |
| AU2006255084A1 (en) * | 2005-06-08 | 2006-12-14 | Novartis Ag | Organic compounds |
| WO2007101347A1 (en) | 2006-03-07 | 2007-09-13 | Aegera Therapeutics Inc. | Bir domain binding compounds |
| US20090010941A1 (en) | 2007-04-09 | 2009-01-08 | University Of Massachusetts | Methods for treating HIV |
| EA017797B1 (ru) | 2007-04-13 | 2013-03-29 | Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган | Бициклические диазомиметики smac, способы их получения, их применения, содержащие их фармацевтические композиции и набор, содержащий указанные композиции |
| WO2009126947A2 (en) * | 2008-04-11 | 2009-10-15 | The Regents Of The University Of Michigan | Heteroaryl-substituted bicyclic smac mimetics and the uses thereof |
| JP2010174138A (ja) | 2009-01-29 | 2010-08-12 | Nok Kluber Kk | グリース組成物の製造方法及び該方法により製造されるグリース組成物 |
| WO2010120476A2 (en) * | 2009-04-01 | 2010-10-21 | Amylin Pharmaceuticals, Inc. | N-terminus conformationally constrained glp-1 receptor agonist compounds |
| US9346852B2 (en) | 2011-03-14 | 2016-05-24 | Bristol-Myers Scuibb Company | Substituted adipic acid amides and uses thereof |
| HK1207829A1 (zh) | 2012-06-06 | 2016-02-12 | Bionor Immuno As | 疫苗 |
| JP6382831B2 (ja) | 2012-11-30 | 2018-08-29 | サンフォード−バーンハム メディカル リサーチ インスティテュート | アポトーシス阻害タンパク質（ｉａｐ）のアンタゴニスト |
| US10300074B2 (en) | 2014-06-04 | 2019-05-28 | Sanford Burnham Prebys Medical Discovery Institute | Use of inhibitor of apoptosis protein (IAP) antagonists in HIV therapy |
-
2013
- 2013-11-26 JP JP2015545193A patent/JP6382831B2/ja active Active
- 2013-11-26 EP EP13859485.8A patent/EP2925764B1/en active Active
- 2013-11-26 WO PCT/US2013/072064 patent/WO2014085489A1/en not_active Ceased
- 2013-11-26 US US14/648,435 patent/US9546174B2/en active Active
- 2013-11-26 CA CA2896577A patent/CA2896577C/en active Active
-
2016
- 2016-11-29 US US15/363,935 patent/US10047119B2/en active Active
-
2018
- 2018-05-25 JP JP2018101004A patent/JP2018162256A/ja active Pending
- 2018-07-10 US US16/031,837 patent/US10544188B2/en active Active
-
2020
- 2020-01-10 US US16/740,240 patent/US11111270B2/en active Active
-
2021
- 2021-07-29 US US17/389,171 patent/US11912786B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016501223A5 (enExample) | ||
| JP2009536620A5 (enExample) | ||
| JP2017509586A5 (enExample) | ||
| RU2477723C2 (ru) | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе | |
| EA201690019A1 (ru) | Производное аминотриазина и содержащая его фармацевтическая композиция | |
| RU2016110096A (ru) | Новое хинолин-замещенное соединение | |
| JP2017522273A5 (enExample) | ||
| RU2011108281A (ru) | Трипиридилкарбоксамидные антагонисты орексиновых рецепторов | |
| RU2016150404A (ru) | Пирроло[2,3-с]пиридины в качестве визуализирующих агентов для нейрофибриллярных клубков | |
| RU2015141592A (ru) | АРИЛ-СУЛЬФАМИДЫ И СУЛЬФАМАТЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ RORc | |
| JP2014510727A5 (enExample) | ||
| RU2013123790A (ru) | Ингибиторы cdk | |
| JP2013510178A5 (enExample) | ||
| JP2013519684A5 (enExample) | ||
| JP2012522003A5 (enExample) | ||
| RU2016126503A (ru) | Аналоги кортистатина, их синтез и применения | |
| ME02558B (me) | Inhibitori replikacije virusa gripa | |
| AR064608A1 (es) | Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer. | |
| AR076550A1 (es) | Inhibidores de la janus tirosina kinasa (jak) | |
| JP2013510120A5 (enExample) | ||
| JP2013056930A5 (enExample) | ||
| JP2014520767A5 (enExample) | ||
| JP2016513130A5 (enExample) | ||
| JP2010511721A5 (enExample) | ||
| JP2016503797A5 (enExample) |